A series of symmetrically bis-substituted imidazole analogs bearing at the N-1 and N-3 two biphenyl moieties ortho substituted either with tetrazole or carboxylate functional groups was designed based on docking studies and utilizing for the first time an extra hydrophobic binding cleft of AT1 receptor. The synthesized analogs were evaluated for their in vitro antagonistic activities (pA 2 values) and binding affinities (elogIC 50 values) to the Angiotensin II AT1 receptor. Among them, the potassium (elogIC 50 ¼ 9.04) and the sodium (elogIC 50 ¼ 8.54) salts of 4-butyl-N,N 0 -bis{[2 0 -(2H-tetrazol-5-yl)biphenyl-4-yl]methyl} imidazolium bromide (12a and 12b, respectively) as well as its free acid 11 (elogIC 50 ¼ 9.46) and the 4-butyl-2-hydroxymethyl-N,N 0 -bis{[2 0 -(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}imidazolium bromide (14) (elogIC 50 ¼ 8.37, pA 2 ¼ 8.58) showed high binding affinity to the AT1 receptor and high antagonistic activity (potency). The potency was similar or even superior to that of Losartan (elogIC 50 ¼ 8.25, pA 2 ¼ 8.25). On the contrary, 2-butyl-N,N 0 -bis{[2 0 -[2H-tetrazol-5-yl)]biphenyl-4-yl]methyl}imidazolium bromide (27) (elogIC 50 ¼ 5.77) and 2-butyl-4-chloro-5-hydroxymethyl-N,N 0 -bis{[2 0 -[2H-tetrazol-5-yl)]biphenyl-4-yl] methyl}imidazolium bromide (30) (elogIC 50 ¼ 6.38) displayed very low binding affinity indicating that the orientation of the n-butyl group is of primary importance. Docking studies of the representative highly active 12b clearly showed that this molecule has an extra hydrophobic binding feature compared to prototype drug Losartan and it fits to the extra hydrophobic cavity. These results may contribute to the discovery and development of a new class of biologically active molecules through bis-alkylation of the imidazole ring by a convenient and cost effective synthetic strategy.
(elogIC 50 ¼ 6.38) displayed very low binding affinity indicating that the orientation of the n-butyl group is of primary importance. Docking studies of the representative highly active 12b clearly showed that this molecule has an extra hydrophobic binding feature compared to prototype drug Losartan and it fits to the extra hydrophobic cavity. These results may contribute to the discovery and development of a new class of biologically active molecules through bis-alkylation of the imidazole ring by a convenient and cost effective synthetic strategy.
Ó 2013 Elsevier Masson SAS. All rights reserved.
Introduction
The RenineAngiotensin System (RAS) plays a key role in regulating cardiovascular homeostasis and electrolyte/fluid balance in normotensive and hypertensive subjects. In the RAS the biological actions of Angiotensin II (ANGII), such as vasoconstriction, release of aldosterone, stimulation of sympathetic transmission and cellular growth are mediated by the Angiotensin type 1 (AT1) receptor. Consequently, the RAS has been the prime target for the therapy of cardiovascular diseases and non-peptide AT1 receptor antagonists have been developed to specifically block it [1, 2] . In specific, the DuPont group pursued a study in this field and developed Losartan, the first orally effective non-peptide antagonist, which is in vivo metabolized to the more potent EXP 3174 [3] ( Fig. 1 ). Since then, numerous new antagonists have been reported by various research groups with nine of them in the clinic i.e. Candesartan [4] , Valsartan [5] , Irbesartan [6] , Telmisartan [7] , Olmesartan [8] which have been established as strong AT1 Receptor Blockers (ARBs). On 25 February 2011, the U.S. Food and Drug Administration (FDA) approved Azilsartan medoxomil [9, 10] which is a newer-generation ARB, for the treatment of high blood pressure in adults. Despite the plethora of treatment options for the management of hypertension, 56% of patients do not have their blood pressure under adequate control [11] suggesting the need for the development of improved ARBs.
The majority of selective ARBs have resulted from the strategy of modifying or replacing several pharmacophore groups of Losartan. Structure Activity Relationship (SAR) studies of Losartan and other imidazole blockers have been reported. Lipophilic substituents, such as the biphenylmethyl group at the 1-position [12] , a linear alkyl group at the 2-position [13, 14] and an acidic group, like tetrazole, CO 2 H, or NHSO 2 CF 3 on the biphenylmethyl group [4, 7, 15] , are required for antagonistic activity. Furthermore, the DuPont group recommended a lipophilic and electron-withdrawing group, such as iodine or CF 3 , as a substituent at the 4-position and a smallsized group at the 5-position, such as CH 2 OH, CH 2 OMe, or CO 2 H, which is capable of forming a hydrogen bond [8, 9] .
We recently described a series of N-substituted 5-butylimidazole analogs as potent ARBs via efficient synthetic routes, allowing the facile introduction of substituents on the imidazole ring [16e19] . Based on these findings, we rationally designed a new class of N,N 0 -symmetrically bis-substituted butylimidazole analogs as potent ARBs that occupy an extra hydrophobic binding cleft (Fig. 1) . Thus, in the present work, a series of new compounds has been synthesized bearing (i) an imidazole ring; (ii) the biphenylmethyl moiety at the N-1 and N-3 of the heterocyclic ring; (iii) an acidic functionality such as a tetrazole group or its bioisostere carboxy group ortho substituted at the biphenylmethyl group, and (iv) the n-butyl chain substituted on the heterocyclic ring at the C-2 or C-5 for efficient binding to the receptor. Furthermore, the hydroxymethyl group was introduced at the C-2 as well as a halogen atom at the C-4 of the imidazole ring, since the chloro substituent in the DuPont series interacts with a lipophilic pocket of the receptor [10] .
These unusual analogs were in vitro evaluated by means of their binding affinities for the human AT1 receptor, as well as for their ability to inhibit the contractility effect of ANGII in isolated rat uterus, compared to Losartan. The SAR study was performed and the results suggested that the position of the n-butyl group in this N,N 0 -bis-alkylated series plays a significant role in the interaction with the AT1 receptor. Finally, structure elucidation and detailed docking studies have been carried out for the one of the most potent synthetic analog 12b. 
Results and discussion

Chemistry
In the current study, we initially examined various synthetic protocols for the syntheses of 4(5)-and 2-substituted imidazoles as key precursors for the preparation of N,N 0 -bis-alkylated analogs as potent ARBs. In Scheme 1, the syntheses of 4(5)-and 2-butylimidazole via a synthetic sequence involving different N-protected imidazole groups are depicted. Imidazole (1) was readily transformed through a four-step synthetic pathway into the corresponding 1-trityl-imidazole-4-carboxaldehyde (2a) [20, 21] . Wittig reaction [22] of the carboxaldehyde 2a by treatment with NaH and the nonstabilized n-propyl triphenylphosphonium bromide (CH 3 CH 2 CH 2 PPh 3 Br) in THF at rt furnished exclusively the Z-3 isomer 3a in excellent yield (81%). The Z-configuration was confirmed by 1 H NMR which showed the presence of two vinylic protons at 6.25 and 5.60 ppm as doublet of triplets, respectively (J ¼ 11.6 Hz). The latter was subjected to catalytic hydrogenation under H 2 atmosphere (3 bar) in the presence of Pd/C at ambient temperature for 2 h to give 4a in 92% yield. Finally, demasking of NH by treatment with 20% TFA in CH 2 Cl 2 in the presence of Et 3 SiH as scavenger furnished the target 4(5)-butylimidazole (5a).
Two routes were investigated for the conversion of 1 into the 2-butylimidazole (5b). In the first approach (Scheme 1, Method A), the N-1 was protected with the (N-dimethylamino)methyl group under Mannich reaction conditions [23] resulting in 2b. Then, the latter compound underwent smooth lithiation, which occurred regiospecifically at the 2-position of the imidazole ring, upon treatment with 1.6 M n-BuLi in the presence of 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU) in THF at À78 C, followed by electrophilic quenching with n-BuI [23, 24] . Subsequent facile acidic hydrolysis of the protective group afforded the corresponding 2-butylimidazole (5b) in 85% yield. In the second approach (Scheme 1, Method B), carboxaldehyde 2c was prepared as described in the published procedure [25] using the N,N-dimethylsulfamoyl group (DMAS) as NH protective group for the lithiation/electrophilic quenching sequence. Wittig reaction of 2c by treatment with NaH and CH 3 CH 2 CH 2 PPh 3 Br in the presence of t-amyl alcohol [26, 27] in THF at 0 C to rt proceeded smoothly leading to the anticipated olefin 3c as a mixture of Z and E isomers in a ratio of ca. 3:1 (as indicated by HPLC) which were isolated and identified by NMR in 62% and 24% yield, respectively. Then, the isomers were subjected to catalytic hydrogenation to afford the saturated 4c in excellent yield (90%). Finally, hydrolysis of 4c in refluxing 1.5 N HCl [28] afforded the target compound 2-butylimidazole (5b). The two methods are quite similar with respect to yields and final products, however, the former was proven to be more efficient in terms of total steps.
In Scheme 2, the syntheses of N,N 0 -bis-alkylated butylimidazole derivatives bearing the biphenylmethyl moiety ortho substituted either with the tetrazole or its bioisostere carboxy group as well as the hydroxymethyl group at the 2-position are depicted. The N,N 0 -bis-alkylation was generally accomplished under basic conditions [29] followed by the treatment of the resulting salt with the appropriate alkylating agent in excess. 4(5)-Butylimidazole (5a) was converted to the corresponding quaternary salts 7 and 8 under the general heterogeneous phase alkylation protocol. In particular, the latter compounds were obtained using excess of the biphenylmethyl bromides 6a and 6b [19] (2.3 equiv.) in the presence of K 2 CO 3 in anhydrous DMF at ambient temperature for 8 h in 78e82% yields. Then, hydroxymethylation was promptly carried out in a sealed tube by treatment with diisopropylethylamine and 37% formalin in DMF at 85 C for 1 h [17, 19] . This reaction proceeded quantitatively as indicated by HPLC and led rapidly and exclusively to the desired hydroxymethylated products 9 and 10. The trityl and t-Bu groups of 7, 9 and 8, 10, respectively, were promptly removed upon addition of 20% trifluoroacetic acid (TFA) in CH 2 Cl 2 in the presence of Et 3 SiH as scavenger to obtain the final compounds 11, 13, 14, 15 in 72e85% yields. Finally, conversion of 11 into the corresponding water soluble bis-potassium and sodium salts 12a and 12b was accomplished by treatment with KOH and NaOH, respectively, in MeOHeH 2 O at rt for 5 h in 80e83% yields. The 1 H NMR spectrum of 12a showed two methylene signals of N-1 and N-3 at 5.33 and 5.32 ppm as singlet peaks, the H-5 of imidazole at 7.41 ppm and H-2 at 8.93 ppm also as singlet peaks. In addition, the hydroxymethylated analog of 14 showed the absence of the proton at C-2 and the appearance of a singlet peak at 4.92 ppm, corresponding to the hydroxymethylene protons. In Scheme 3, the syntheses of N,N 0 -bis-alkylated halogenated butylimidazole derivatives bearing the biphenylmethyl moiety ortho substituted either with the tetrazole or its bioisostere carboxy group Scheme 1. Reagents and conditions: (a) CH 3 CH 2 CH 2 PPh 3 Br, NaH (powdered, 95%), THF, rt, 8 h; (b) H 2 (3 bar), 10% Pd/C, MeOH, rt, 2 h; (c) 20% TFA in CH 2 Cl 2 , Et 3 SiH, rt, 1 h; (d) n-BuLi (1.6 M in hexanes), DMPU, n-BuI, then 2 M HCl; (e) CH 3 CH 2 CH 2 PPh 3 Br, NaH (powdered, 95%), t-amyl alcohol, THF, 0 C to rt, 10 h; (f) 1.5 N HCl, THF, reflux, 2 h. as well as the hydroxymethyl group at the 2-position are depicted. The N,N 0 -bis-alkylation was advantageously accomplished under basic conditions by solideliquid phase transfer catalysis (PTC) [30, 31] . 4(5)-Butylimidazole (5a) was converted to the corresponding halogenated analogs 16cee by treatment with NXS (X ¼ Cl, Br, I) in DMF in 71e73% yields. The 1 H NMR spectra of 16cee showed the absence of the H-4 signal of the imidazole ring at 6.74 ppm. Furthermore, the 13 C NMR spectra showed an upfield trend in C-4 chemical shifts produced by bromine and iodine atoms for 16d and 16e, at 114.53 and 81.92 ppm, respectively, while the C-4 in the chloro derivative 16c appeared at 124.24 ppm. Alkylation of 16cee with the alkylating agent 6a, in the presence of K 2 CO 3 and catalytic amount 18-crown-6-ether to assist by chelating potassium in anhydrous THF under reflux for 12 h, furnished the 17cee in 52e57% yields. PTC was also successfully adopted for the syntheses of 18cee by treatment with 6b in the presence of fine powdered KOH and catalytic amount of 18-crown-6-ether in anhydrous Tol at 80 C for 12 h in 58e64% yields. Acidolysis of protective groups in 17cee and 18cee was accomplished in the same manner and afforded 19cee and 20cee, respectively, in 73e82% yields. On the other hand, hydroxymethylation of 17cee and 18cee by treatment with 37% formalin in the presence of diisopropylethylamine in DMF at 80 C for 1 h afforded 21cee and 22cee in 70e78% yields. The latter were subjected to acid hydrolysis with TFA, resulting in 23cee and 24cee in 75e81% yields.
Identical methodology was employed for the preparation of 2-butylimidazole analogs 27 and 28 (Scheme 4) through a two-step sequence. In particular, alkylation of 5b by treatment with the alkylating agents 6a and 6b and subsequent acid hydrolysis afforded the expected analogs 27 and 28.
Finally, in Scheme 5, the syntheses of bis-alkylated analogs 30 and 31 with the implementation of a facile PTC alkylatione deprotection reaction sequence in one-pot procedure are depicted. Thus, alkylation under basic conditions of the commercially available (2-n-butyl-4-chloro-1H-imidazole-4yl)methanol 29, which is an important precursor for the preparation of Losartan, followed by acid hydrolysis, afforded the corresponding analogs 30 and 32 in 77% and 74% yield over two steps, respectively.
Structure elucidation of analog 12b
The chemical structure of 12b (Fig. 2) has been elucidated using a combination of 2D DQF-COSY and 2D ROESY experiments ( Table 1 ). The alkyl chain of the molecule was easily identified from the 2D DQF-COSY experiment, the multiplicity and integration of the peaks (Fig. 2) . Due to the asymmetry of the molecule the aromatic biphenyl protons showed distinct resonances confirmed by the integration of the peaks (see the alkyl chain extended only to one side of biphenyltetrazole moiety). The H10 and H10 0 protons are magnetically un-equivalent and are depicted as separate single peaks (Fig. 2) . 2D DQF-COSY (Supporting information SF1) made possible to assign all aromatic peaks in combination with 2D ROESY experiment. H10 showed ROE with the single peak at 6.85 ppm, which according to the integration corresponds to the resonance of four protons. These were assigned as the H12, H13, H15, H16 protons of the aromatic ring A (Supporting information SF2). 2D ROESY spectrum reveals that this peak is correlated with the protons of the alkyl chain H6, H7, and H8 (Supporting information SF3). Similarly H10 0 showed ROE with the doublet at 7.04 ppm attributed to the protons 13 0 , 15 0 and 18 0 (Supporting information SF2). The 2D DQF-COSY experiment confirmed the proposed assignment (Supporting information SF2). The doublet resonating at 6.86 ppm and assigned to 12 0 and 16 0 protons is correlated through coupling with the doublet at 7.04 ppm. Such correlation is evident also with Losartan molecule that contains biphenyltetrazole segment [32] . As the integration of the doublet shows the existence of three protons, the other one is assigned to H18 0 . This is because H18 0 shows correlation with the triplet peak resonating at 7.25 ppm and assigned to H19 0 . Consequently, H19 0 is correlated with multiplet at 7.31 ppm, assigned to H20 0 , which in turn is correlating with the doublet peak at 7.55 ppm assigned to H21 0 . The doublet at 7.55 ppm is integrated to two protons assigned to 21, 21 0 . This is in accordance with results obtained with Losartan [30] . In addition, these protons are expected to be the most magnetically deshielded ones, because they are close to the tetrazole ring. Apparently, the protons of the two B and B 0 rings have identical or close chemical shifts since they are far away from the butyl chain that differentiates mainly the environment of aromatic protons of the A and A 0 rings.
The broad singlet at 6.99 ppm has no coupling through bond correlation. 2D ROESY experiment shows that this peak is correlated through space with H10 0 and with the protons of the alkyl chain H6, H7, and H8 (Supporting information SF2 and SF3). This peak is attributed to H5 of imidazole ring. The two different patterns of biphenyl rings are observed in our previous studies using commercial and synthetic ARBs. In Losartan [32] , Valsartan [33] and Eprosartan [34] the A ring shows clearly the doublet of doublet pattern common for 1,4 bis-substituted aromatic compounds. However, in the synthetic analog V8 a singlet peak is observed that is attributed to the same ring [17, 35] . It is obvious that the equivalency of the protons depends on the environment that surrounds biphenyltetrazole ring. A small peak at 8.47 ppm as a remaining peak is assigned to H2. It is the most downfield peak, which can be explained with the position of H2 between two nitrogens.
Docking studies of analog 12b at the binding site of AT1
The synthesis of 12b and its derivatives has been based on docking studies. The docking studies of 12b at AT1 and its interactions with the amino acids of the active site are of particular interest. Fig. 3 illustrates the best binding pose of 12b at the binding site of AT1 (DG ¼ À16.21 kcal/mol) with the hydrophilic and hydrophobic areas around the molecule. The two biphenyl moieties point to the widely extended hydrophobic area, whereas the hydrophilic area mainly surrounds the imidazole ring and is less extend around the tetrazole.
Docking calculations using the same program and protocol have pointed out the best binding pose of Losartan at the active site [17] . In comparison to 12b, Losartan is anchored to the binding site with a lower binding affinity (DG ¼ À12.30 kcal/mol) reflecting its lower potency.
In Fig. 4 , the superimposition of the best binding poses of 12b and Losartan is depicted. Both ligands show similar orientation at the binding site of AT1 except the biphenyl moiety tetrazole (see A 0 , B 0 rings) of 12b which has no equivalent groups. Interestingly, this additional lipophilic part resides in a lipophilic cavity surrounded by the amino acids Leu112, Ala181, Phe182, Ile288, Ala291. These hydrophobic interactions are responsible for the enhanced binding affinity of 12b in comparison to Losartan. It is this ability of 12b to reside in an extra cavity that triggered our interest for synthesizing new drugs having a variety of activity. This drug molecule has resulted after trying manually various derivative compounds which could fit the extra cavity. 12b has been suggested by the synthetic group as the drug lead bearing the technognosy of the synthetic feasibility of such molecules. The syntheses of this molecule and its derivatives shows that collaboration of the medicinal chemists and computational chemists can lead to new ideas and to the rational design of new classes of molecules with optimized biological activity, taking into account pharmacophore orientation and charges.
Molecular dynamics (MD) of 12b at the binding site of AT1
It has been postulated that the molecular basis of AT1 antihypertensive action can be interpreted by a two-step model. In the first step, the ARB is incorporated into the membrane bilayer through the lipidewater interface and secondly laterally diffuses to reach the binding site of the AT1 receptor in order to exert its biological activity [36e38] . For this reason, we have studied not only the interaction of 12b at the binding site of AT1 receptor but also its incorporation into plasma membrane.
Before starting the analysis of our results obtained by the MD simulation, a graphical representation of the simulated system is provided in Fig. 5 (a) where 12b (black color) included in the interior of the bilayer (dipalmitoyl phospatidylcholine (DPPC): green color). Fig. 5(b) and (c) depicts the most preferable conformations of 12b in decreasing order as obtained from a clustering algorithm available, which is available in the UCSF Chimera software [39] . As already mentioned, 12b was initially placed into the water phase and during the course of the simulation penetrated into the interior of the bilayer. The mass density profiles of all components along the Z-axis are provided in Fig. 6 ; it is clearly seen that 12b under study is found inside the bilayer (red curve). The peak of its distribution is nearly 1.1 nm far from the center of the bilayer which is defined as the minimum of the DPPC distribution (blue color). Another interesting observation is that 12b is found in a depth that permits an interaction with some water molecules as seen by the intercept of the distribution of water (black curve) and drug. A complementary view is given by Fig. 7 , in which the distance between DPPC and drug centers of mass is monitored over the last 40 ns of the MD simulation. The zero in the aforementioned diagram corresponds to the center of bilayer. In order to give a clearer picture of the simulated system, the average distance of phosphorous atoms (DPPC molecules) in both leaflets is depicted as well, indicating a stable membrane with a thickness around 3.8 nm. It may also be concluded that the drug fluctuates around a distance of 1.1 nm from the bilayer center. However, it does not move significantly and therefore there is no tendency for crossing events, i.e. the move of a host molecule from one leaflet to the other through the middle of the bilayer. The potential of mean force (PMF) of 12b from water to lipid phase is depicted in Fig. 8 , in which the zero at the abscissa corresponds to the bilayer center while remote there is pure water. The position of minimum is about 1 nm far from the bilayer center and it is compatible to the position found by the MD simulation with 12b initially placed in the aqueous phase. Another interesting observation is the high energy barrier (41 kJ mol À1 ) that 12b has to overcome so as to move from one leaflet to the other through the middle of the bilayer. Besides, the free energy for partitioning into the membrane was estimated by the difference of PMF at the water phase (large distances) and at the location of the minimum. This value is approximately equal to À81 kJ mol
À1
. Having defined the preferred position of 12b in the membrane from the mass density profiles and the PMF, we analyzed the interaction of this drug with DPPC and water molecules in terms of hydrogen bonding. To this end, a GROMACS tool was applied which makes use of standard geometrical criteria such as distance between acceptor and donor (<0.35 nm) and the angle among acceptorehydrogenedonor (<30 ). The average number of hydrogen bonds of 12b with DPPC and the penetrated water molecules is 1.366 and 1.519, respectively, showing that indeed there is a significant interaction with these components. In particular, DPPC oxygen atoms participate in a hydrogen-bond network with two nitrogen atoms of 12b which are indicated by two arrows in Fig. 5(b ). An additional confirmation of the previous observation is provided in Fig. 9 by the fully overlapping density profiles of oxygen (DPPC) and nitrogen atoms (12b). Table 2 summarizes the results of HOMO and LUMO levels of the compounds studies. Based on these results, binding affinities and the in vitro ANGII antagonist properties, several remarks can be made. First of all, inclusion of halogens (Br, Cl, and I) in R 1 position
HOMO and LUMO quantum chemical calculations
reduced HOMO values as expected. As already mentioned HOMO energy values decrease with the presence of electron withdrawing groups (EWGs) such as halogens. A decrease in in vitro binding affinity as determined in radioligand binding studies for compounds 19c and 19d was also reported. The inclusion of a small sized group such as eCH 2 OH (14 and 15) did not significantly change HOMO and LUMO values but resulted also in a reduced binding affinity. The affinity was further reduced when halogens were also included in the R 1 position (23c, 23d) as expressed in in vitro activity (pA 2 ). Inclusion of K and Na (12a and 12b) significantly reduced HOMO values and a decrease in binding affinity (elogIC 50 ) was also reported. A switch of the substituents in R 2 and R 3 position for 11 and 27, 19c and 30 also resulted in a decreased activity while HOMO increased and LUMO decreased.
We have further explored the HOMO LUMO energies by developing a simple Decision Tree with the primary purpose of discriminating compounds into two categories, low affinity and high affinity, (threshold elogIC 50 < 6.48). HOMO and LUMO values were used as input variables for the development of the Decision Tree ( Fig.10 ) [40] . The visual inspection of the Decision Tree helps in the analysis and interpretation of the structural data, the existence of clusters and outliers, the relationship between samples and the influence of each variable (HOMO & LUMO). The accuracy of the Decision Tree is 92%. The graphical representation of the Decision Tree for the data set is presented in Fig.11 . According to the Decision Tree, the design of new molecules as ARBs can been accomplished by high HOMO and LUMO energy values. More specifically, in the case of HOMO values are greater than À0.31916 eV and LUMO greater than À0.14252, the compounds exert high binding affinity to the receptor. HOMO and LUMO fields are graphically depicted in Fig. 11 for 11.
Pharmacological characterization and SAR
In order to pharmacologically characterize the synthesized analogs, we determined their binding affinities (elogIC 50 ) for the human AT1 receptor in radioligand competition binding assay (Table 3 , Fig. 12 (a) and (b)), as well as their ability to antagonize the activity of ANGII in the rat uterus in vitro test (pA 2 ) of the high affinity compounds (elogIC 50 ! 6.50) using Losartan as a reference compound (Table 3) . Interestingly, the introduction of an additional biphenyltetrazole moiety on the 4(5)-butylimidazole led to the N,N 0 -bis-substituted imidazolium salt 11, which is bound to AT1 receptor with higher affinity (elogIC 50 Fig. 12 ). Replacement of the tetrazole with the bioisostere carboxy group, thus resulting in 13 and 15 significantly decreased binding affinity (Fig. 12) in line with previous studies in which tetrazole is a superior non-classical isostere of carboxylate [10, 19] . More importantly, the halogenated analogs 19c, 19d, 23c, 23d (Table 3 , Fig. 12 ) showed remarkable drop in binding affinity in contrast to the halogenated series of Losartan which retained affinity [10] indicating the ambiguous function of substituents at C-4 of imidazole [19] . Interestingly, the bis-alkylation of 2-butylimidazole and 2-butyl-4-chloro-5-hydroxymethylimidazole, the key precursor in the synthesis of Losartan, resulted in compounds 27 (elogIC 50 ¼ 5.77) and 30 (e logIC 50 ¼ 6.38) ( Table 3 , Fig. 12 ) displaying dramatic loss of binding affinity compared to 11, in which the n-butyl group at the C-5 is exposed, thus enhancing binding to the receptor. These results suggested that the position of the n-butyl group plays a significant role in their interaction with the AT1 receptor. 
Conclusions
The present study refers to the design and syntheses of bisalkylated 4(5)-butylimidazole analogs as potent ARBs. In particular, a rational design was performed to synthesize a series of N,N 0 -symmetrically bis-substituted imidazole analogs bearing at the N-1 and N-3 two biphenylmethyl moieties ortho substituted either with tetrazole or carboxylate functional groups. This work describes for the first time potent N,N 0 -bis-alkylated analogs in contrast to the marketed ARBs, which their heterocyclic core is monoalkylated. Furthermore, we elaborated general synthetic methodology for the assembly of the n-butyl group onto the imidazole ring via the Wittig reaction as well as the bis-alkylation of the N-1 and N-3 of 4(5)-butylimidazole and 2-butylimidazole with the biphenylmethyl moiety. A remarkably efficient approach was also adopted for the introduction of the hydroxymethyl group at the C-2 position, as we have previously shown [19] . The SAR studies demonstrated the importance of the nature and the position of pharmacophores. In particular, the presence of two anionic tetrazole groups along with the lipophilic n-butyl group at the C-5 led to the potent analogs 11 and its water soluble salts 12a and 12b. The introduction of the electronegative hydroxymethyl group at the C-2 (analog 14) led to acquisition of affinity and potency, while the presence of a halogen atom at the C-4 of the imidazole ring (analogs 19cee and 23cee) led to an essential decrease in affinity. Therefore, the presence of two tetrazole rings seems to be optimal for high affinity in contrast to the carboxy group (analogs 13, 15) which represents poor bioisostere for the tetrazole group, since these analogs showed remarkably low affinity. The position of the n-butyl group plays a significant role, since reorientation from the 4-(analogs 11, 12a, 12b) to the 2-position (27, 30) of the imidazole ring resulted in a sharp drop of binding affinity. This dramatic loss of activity may be explained by the concealment of the n-butyl group between the two biphenyltetrazole moieties. Of paramount importance were the biological results of the synthetic analog 12b. Its higher affinity and potency to antagonize ANGII compared to Losartan can be explained by docking studies which demonstrated an additional hydrophobic cavity. MD calculations on lipid bilayers showed that this molecule is incorporated at the interface and exerts a network of interactions with polar region. Thus, this molecule does not only interact with the same binding site as other sartans but also acts through lipid bilayer at the same topographical location [41e44]. Particularly, it anchors at the interface as other sartans where exerts its amphiphilic interactions both with the polar region and upper hydrophobic segments of the phospholipid bilayers. Biophysical studies are in progress to provide more information on this issue. Another important finding from these studies is the critical role of the orientation of the lipophilic n-butyl group. The highly hydrophobic residues of receptor that surround this group and interact through van der Waals interactions can explain its orientation significance. 
1-Trityl-4-butylimidazole (4a)
A solution of 3a (0.30 g, 0.82 mmol) in anhydrous MeOH (10 mL) was transferred in a hydrogenation flask and Pd/C (10% wt/wt, 0.04 g, 0.04 mmol) was added. The reaction mixture was allowed to proceed at rt, under a H 2 atmosphere at a pressure of 3 bar (Parr hydrogenator apparatus) for 2 h. Then, the catalyst was filtered through a pad of Celite Ò and washed with MeOH. 
2-Butylimidazole (5b)
To a solution of 2b (0.25 g, 2 mmol) in anhydrous THF (10 mL) under Ar atmosphere was added n-BuLi (1.6 M in hexanes, 1.37 mL, 2.20 mmol) dropwise via a syringe at À78 C. After 30 min, DMPU (0.48 mL, 4.0 mmol) was added at À70 C and stirred for additional 30 min before n-BuI (0.27 mL, 2.40 mmol) was added at À78 C. The reaction mixture was allowed to warm to rt over a period of 16 h. 
To a stirred suspension of propyl triphenylphosphonium bromide (1.43 g, 3.72 mmol) and anhydrous t-amyl alcohol (0.45 mL, 4.09 mmol) in anhydrous THF (14 mL) was added NaH (powdered 95%, 0.10 g, 4.09 mmol) at 0 C under Ar atmosphere and stirred at rt for 2 h. To the resulting yellow phosphorous ylide was added a solution of 2c (0.38 g, 1.86 mmol) in anhydrous THF (2 mL) dropwise at 0 C. The mixture was stirred at rt over a period of 8 h before being quenched with saturated aqueous NaHCO 3 solution and extracted with CH 2 Cl 2 (3 Â 20 mL). The organic layer was washed with H 2 O (2 Â 10 mL), dried over Na 2 SO 4 and concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, EtOAc/Hex 3:2) to afford the pure Z-and E-9 isomers as yellow oils (0.26 g and 0.10 g, respectively). Z-Isomer: yield: 62%; R f 0. 46 
1-(N,N-Dimethylsulfamoyl)-2-butylimidazole (4c)
Compound 4c was prepared in an analogous manner to that described for 4a. A mixture of the isolated Z-and E-was subjected to catalytic hydrogenation. Yield: 90%; R f 0. 44 
2-Butylimidazole (5b)
A solution of 4c (0.20 g, 0.86 mmol) in THF (2 mL) was refluxed with 1.5 N HCl (3 mL) for 2 h and then cooled. After neutralization by addition of saturated aqueous NaHCO 3 solution, the solvent was concentrated in vacuo to give a residue, which was extracted with CH 2 Cl 2 (3 Â 10 mL). The combined organic extracts were washed with brine, dried over Na 2 SO 4 and concentrated in vacuo to afford 7 as a pale yellow oil (0.09 g, 86%). To a solution of 4 (5) 
4-Butyl
The same procedure was employed for the alkylation of 5a by treatment with the alkylating agent 6b. Yield 82%; R f 0. In a sealed tube were sequentially added 7 (0.50 g, 0.43 mmol), DMF (1 mL), 37% formalin (0.11 mL, 1.48 mmol) and diisopropylethylamine (0.51 mL, 3.01 mmol). The resulting mixture was stirred at 80 C until HPLC showed no starting material left (ca. 1 h). Then, the mixture was diluted with CH 2 Cl 2 (30 mL), washed with 5% aqueous citric acid (2 Â 10 mL), brine (Â10 mL), the organic phase was dried over Na 2 SO 4 , filtered and concentrated in vacuo. The resulting residue was precipitated from cold Et 2 O to afford 9 as a white powder. Yield 84%; R f 0. 36 4.12. General procedure 7: bis-alkylation of 16cee with the alkylating agent 6b
To a solution of 16c (0.20 g, 1.26 mmol) in anhydrous Tol (4 mL) under Ar atmosphere were sequentially added powdered KOH (0.14 g, 2.52 mmol), a catalytic amount of 18-crown-6-ether as a phase transfer catalyst and the alkylating agent 6b (1.00 g, 2.90 mol). The reaction mixture was stirred at 80 C over a period of 12 h before being quenched with H 2 O (10 mL) and extracted with CH 2 Cl 2 (3 Â 20 mL). The combined organic extracts were dried over Na 2 SO 4 
The same procedure as above was employed for the preparation of 18e. Yield: 58%; R f 0. 
General procedure 3 was employed for the preparation of 19d. Yield: 80%; R f 0.43 (CHCl 3 /MeOH/gl. 
Docking studies
The 3D model of the AT1 receptor used in our docking studies was kindly provided by Tuccinardi et al. [45] . The construction of this model is based on X-ray bovine rhodopsin structure, molecular procedure and available site-directed mutagenesis data [46] . Molecular Docking studies were performed using Glide extra precision (XP) implemented Induced Fit Docking (IFD) protocol (v5.0) [47e49] docking programs under the Linux operating system.
The binding site was defined by 20 A inner cubic grid box, centered on the point that is the center of mass of residues Lys199 and His256. The IFD protocol under the Schrodinger molecular modeling package was used in order to eliminate clashes between receptor and ligand atoms and for the receptor to gain partial flexibility to the receptor. Before the docking simulations, the complexes were submitted to the protein preparation module of Schrodinger. Ligands were constructed using the Schrodinger's Maestro module and then geometry optimization was performed for these ligands using PolakeRibiere conjugate gradient (PRCG) minimization (0.0001 kJ A À1 mol À1 convergence criteria). Protonation states of residues were created using LigPrep and Protein Preparation modules under the Schrodinger package at neutral pH. IFD uses the Glide docking program to account the ligand flexibility and the refinement module and the Prime (v.1.6) program [48, 49] to account for flexibility of the receptor. 
Molecular dynamics simulations
A lipid bilayer of 72 DPPC molecules was simulated under the CHARMM 36 force field [50, 51] with all hydrogen atoms explicit, whereas the aqueous phase (2162 water molecules) was described by the TIP3P [52] (transferable intermolecular potential 3P) model. The initial structure for the bilayer was downloaded as a PDB file by the following web page: http://terpconnect.umd.edu/wjbklauda/ research/download.html. As far as the 12b molecule, its topology file was created by the SwissParam server which is available online: http://swissparam.ch/ [53] . The abovementioned topology files are compatible with the CHARMM force field.
All simulations were performed with the molecular dynamics package GROMACS 4.5. 4 [54e57] in the context of NP z AT ensemble with a constant area per lipid, A, equal to 0.64 nm 2 /lipid. The equations of motion were integrated with a time step equal to 2 fs while temperature was kept constant at 317 K using the Berendsen thermostat [58] with a coupling time constant equal to 0.1 ps. Regarding to the pressure along the normal to two DPPC leaflets (Zaxis), it was regulated by the Berendsen barostat [58] at 1 bar, with a coupling time constant to be 1 ps. LennardeJones and Coulomb interactions were calculated using a 1.0 nm cut-off radius while the long range electrostatics were treated with the Particle Mesh Ewald (PME) method [59] . The system was energy-minimized employing the steepest descent method [57] and after that the MD simulation was commenced with the 12b molecule initially placed in the aqueous phase. The whole duration of the simulation is equal to 120 ns whereas the last 40 ns were employed for the calculation of the properties.
Umbrella sampling simulations
The PMF of the 12b from aqueous to lipid phase was computed by the Weighted Histogram Analysis Method (WHAM) [60, 61] that is available in GROMACS 4.5.4. In particular, thirty one biasing MD simulations were conducted along a reaction coordinate z (Z-axis), which is defined as the distance of the 12b center of mass from the bilayer center (z ¼ 0). In addition, a harmonic potential was applied (k ¼ 500 kJ/mol/nm 2 ) between bilayer and 12b centers of mass. It has also to be reported that the simulation system contains 3021 water molecules so as to avoid the interaction of the drug with the periodic image of the opposite leaflet of the bilayer. The duration of the biasing MD simulations was 24 ns of which the first 10 ns was regarded as an equilibration and therefore they were not taken into account for the computation of PMF. The rest of the MD parameters were the same with those given in the previous subsection.
Quantum chemical calculations
Geometry optimization and HOMO and LUMO calculations were performed for the studied compounds. The geometries were fully optimized using Density Functional Theory (DFT) hybrid method with the Becke's three-parameter exchange functional and gradient-corrected functional of Lee, Yang and Parr (B3LYP) [62] using the following standard basis set: 3e21 g. All geometry optimization were followed by calculations of frequencies in order to identify obtained structures as energy minima (no imaginary frequencies). All minima for all the compounds were verified by establishing that the matrix of energy second derivatives (Hessian) has only positive eigenvalues (all vibrational frequencies are real). All calculations were carried out with the Gaussian 09W program.
HOMO and LUMO frontier orbitals of the molecule were also computed at the same level of theory. Molecular orbital (MO) surfaces visually represent the various stable electron distributions of a molecule. According to Frontier orbital theory [63] the shapes and symmetries of the highest-occupied and lowest-unoccupied molecular orbitals (HOMO and LUMO) are crucial in predicting the reactivity of a species and the stereochemical and regiochemical outcome of a chemical reaction. Molecules with high HOMO (highest occupied molecular orbital energy) values are able to donate electron density more easily than molecules with low HOMO energy values. The HOMO energy value can be increased with the presence of electron-donating groups (EDG) such as e NMe 2 , eNH 2 , eNHEt, and eOMe and decreased with the presence of electron-withdrawing groups (EWG) such as halogens, eCN and eNO 2 groups [64] . 4 , 137 mM NaCl, 2.7 mM KCl, pH 7.2e 7.3 at room temperature), briefly treated with PBS containing 2 mM EDTA (PBS/EDTA), and then dissociated in PBS/EDTA. Cell suspension was centrifuged at 1000Â g for 5 min at room temperature, and the pellet was homogenized in 1 mL of buffer O (50 mM TriseHCl containing 0.5 mM EDTA, 10% sucrose, 10 mM MgCl 2 , pH 7.4 at 4 C) using a Janke & Kunkel IKA Ultra Turrax T25 homogenizer (at setting w20, 10e15 s, 4 C). The homogenate was centrifuged at 250Â g for 5 min at room temperature. The pellet was discarded and the supernatant was centrifuged (16,000Â g, 10 min, 4 C). The membrane pellet was resuspended (0.6e0.7 mL/100 mm dish) in buffer B (50 mM Trise HCl containing 1 mM EDTA, 10 mM MgCl 2 , 0.2% BSA, 0.2 mg/mL bacitracin, and 0.93 mg/mL aprotinin, pH 7.4 at 4 C) and used for radioligand binding studies. without increasing concentrations of ANGII analogs in a final volume of 0.15 mL. The mixtures were incubated (1 h, 24 C) and then, filtered using a Brandel cell harvester through Whatman GF/C glass fiber filters, presoaked for 1 h in 0.5% polyethyleneimine at 4 C. The filters were washed 10 times with 1e2 mL of ice-cold 50 mM Trise HCl containing NaCl 120 mM, pH 7.4 at 4 C. Filters were assessed for radioactivity in a gamma counter (LKB Wallac 1275 minigamma, 80% efficiency). The amount of membrane used was adjusted to ensure that specific binding was always equal to or less than 10% of the total concentration of the radioligand added. Specific ] ANGII. Data analysis for competition binding was performed by nonlinear regression analysis, using GraphPad Prism 4.0 (GraphPad Software, San Diego, CA). elogIC 50 values were obtained by fitting the data from competition studies to a one-site competition model and presented as mean plus/minus standard error (SE).
Rat uterotonic test in vitro
The compounds prepared were tested in rat uterotonic in vitro test [65] . All samples were dissolved in DMSO to make stock solution of 1e4 mg/mL. Further solutions were made in physiological solution. Standard ANGII was dissolved in physiological solution. The test was performed in the same way as described for oxytocin and vasopressin analogs or bradykinin compounds [65e68]. The pA 2 was calculated from at least 3 independent experiments using uteri from different rats. In brief, the excised and longitudinally cut strips of rat uterus were placed into a bathing chamber into media without magnesium ions and mounted to the contraction recorder. The height of a single isometric contraction of a uterine strip was measured. The cumulative doseeresponse curves of standard ANGII were constructed, i.e. doses of standard (in the presence or absence of an analog) were added successively to the uterus in the organ bath in doubling concentrations and at 1 min intervals without the fluid being changed until the maximal response (the highest contraction) was obtained. The shift of the curves in the presence of an analog was determined. The concentration of the analog leading to the shift corresponding to 0.3 in logarithmic scale (it means that twice higher concentration of the standard was necessary to apply to reach the half maximal effect) was determined. Negative logarithm on the base of 10 of that concentration is pA 2 . Wistar rats were used in all experiments. Handling of the experimental animals was done under supervision of the Ethics Committee of the Academy of Sciences according to x 23 of the law of the Czech Republic no. 246/1992.
